Calendario de promoción Blueprint Medicines Corporation
Acerca de la empresa
Blueprint Medicines Corporation разрабатывает препараты низкомолекулярных ингибиторов киназы, которые нацелены на геномные факторы при геномно определенных раках, редких заболеваниях и иммунотерапии рака. Компания разрабатывает авапритиниб для лечения системного мастоцитоза (СМ) и опухолей стромы желудочно-кишечного тракта; BLU-263, орально доступный мощный ингибитор KIT для лечения вялотекущего SM и других заболеваний тучных клеток; и физогатиниб, орально доступный и мощный ингибитор, который находится в фазе I клинических испытаний для лечения запущенной гепатоцеллюлярной карциномы.
Más detallesP/E | 20.88 |
---|---|
P/S | 58.1 |
P/BV | 8.32 |
EV/EBITDA | -10.64 |
EBITDA | -0.3613 |
Цена ао | 89.24 |
Сайт | https://www.blueprintmedicines.com |
Число акций ао | 0.06056 млрд |
Выручка | 0.0665 |
Див.доход ао | 0 |
ISIN | US09627Y1091 |
Валюта | usd |
IPO date | 2015-04-30 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Cambio de precio por día: | -4% (92.96) |
---|---|
Cambio de precio por semana.: | +1.9% (87.58) |
Cambio de precio por mes: | +3.48% (86.24) |
Cambio de precio en 3 meses.: | -21.35% (113.46) |
Cambio de precio en seis meses: | +3% (86.64) |
Cambio de precio por año: | +80.25% (49.51) |
Cambio de precio en 3 años.: | -14.02% (103.79) |
Cambio de precio en 5 años.: | +8.78% (82.04) |
Cambio de precio desde principios de año.: | +50.08% (59.46) |
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
Fecha de transacción | fecha de divulgación | Persona enterada | Tipo | Precio | Volumen | Cantidad | Comparte hasta, % | compartir después, % | Documento |
---|---|---|---|---|---|---|---|---|---|
09.09.2024 | 11.09.2024 | Albers Jeffrey W. Director |
Venta | 85.57 | 1 685 900 | 19702 | 0 | -0.03 | enlace |
09.09.2024 | 11.09.2024 | Albers Jeffrey W. Director |
Compra | 36.05 | 360 500 | 10000 | 0 | 0.02 | enlace |
09.09.2024 | 09.09.2024 | Albers Jeffrey W. Director |
Compra | 85.57 | 1 685 900 | 19702 | 0 | 0.03 | enlace |
15.08.2024 | 15.08.2024 | MICHAEL LANDSITTEL Officer |
Compra | 95.23 | 419 869 | 4409 | 0 | 0.01 | enlace |
05.07.2024 | 08.07.2024 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Venta | 111.2 | 428 120 | 3850 | 0 | -0.01 | enlace |
05.07.2024 | 08.07.2024 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Compra | 54.13 | 208 401 | 3850 | 0 | 0.01 | enlace |
03.07.2024 | 08.07.2024 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Venta | 111.29 | 981 244 | 8817 | 0 | -0.01 | enlace |
03.07.2024 | 08.07.2024 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Compra | 54.13 | 477 264 | 8817 | 0 | 0.01 | enlace |
28.06.2024 | 02.07.2024 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Venta | 111.15 | 37 013 | 333 | 0 | 0 | enlace |
28.06.2024 | 02.07.2024 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Compra | 54.13 | 18 025 | 333 | 0 | 0 | enlace |
21.06.2024 | 25.06.2024 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Venta | 104.19 | 7 713 600 | 74034 | 0 | -0.13 | enlace |
21.06.2024 | 25.06.2024 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Compra | 34.48 | 2 085 420 | 60482 | 0 | 0.1 | enlace |
05.06.2024 | 07.06.2024 | Carter Percy H. CHIEF SCIENTIFIC OFFICER |
Venta | 105.13 | 420 520 | 4000 | 0 | -0.01 | enlace |
04.06.2024 | 06.06.2024 | Hewes L. Becker CHIEF MEDICAL OFFICER |
Venta | 104.91 | 254 302 | 2424 | 0 | 0 | enlace |
03.06.2024 | 04.06.2024 | Hewes L. Becker CHIEF MEDICAL OFFICER |
Venta | 106.43 | 523 848 | 4922 | 0 | -0.01 | enlace |
31.05.2024 | 04.06.2024 | Hewes L. Becker CHIEF MEDICAL OFFICER |
Venta | 105.91 | 3 612 380 | 34108 | 0 | -0.06 | enlace |
31.05.2024 | 04.06.2024 | Hewes L. Becker CHIEF MEDICAL OFFICER |
Compra | 59.21 | 1 461 720 | 24687 | 0 | 0.04 | enlace |
08.05.2024 | 10.05.2024 | Landsittel Michael CHIEF FINANCIAL OFFICER |
Compra | 2.32 | 65 380 | 28181 | 0 | 0.05 | enlace |
07.03.2024 | 26.03.2024 | Albers Jeffrey W. Director |
Venta | 90.69 | 1 000 580 | 11033 | 0 | -0.02 | enlace |
28.02.2024 | 01.03.2024 | Murray Christopher K. CHIEF TECHNICAL OPERATIONS |
Venta | 100 | 500 000 | 5000 | 0 | -0.01 | enlace |
28.02.2024 | 01.03.2024 | Murray Christopher K. CHIEF TECHNICAL OPERATIONS |
Compra | 54.13 | 270 650 | 5000 | 0 | 0.01 | enlace |
25.01.2024 | 29.01.2024 | Albers Jeffrey W. Director |
Venta | 81.91 | 2 047 750 | 25000 | 0 | -0.04 | enlace |
25.01.2024 | 29.01.2024 | Albers Jeffrey W. Director |
Compra | 7.13 | 178 250 | 25000 | 0 | 0.04 | enlace |
11.12.2023 | 13.12.2023 | Albers Jeffrey W. Director |
Venta | 79.07 | 395 350 | 5000 | 0 | -0.01 | enlace |
11.12.2023 | 13.12.2023 | Albers Jeffrey W. Director |
Compra | 36.05 | 180 250 | 5000 | 0 | 0.01 | enlace |
04.12.2023 | 06.12.2023 | Murray Christopher K. CHIEF TECHNICAL OPERATIONS |
Venta | 71.43 | 42 858 | 600 | 0 | 0 | enlace |
30.11.2023 | 04.12.2023 | Albers Jeffrey W. Director |
Venta | 70.55 | 352 750 | 5000 | 0 | -0.01 | enlace |
30.11.2023 | 04.12.2023 | Albers Jeffrey W. Director |
Compra | 36.05 | 180 250 | 5000 | 0 | 0.01 | enlace |
05.06.2023 | 07.06.2023 | Hewes L. Becker CHIEF MEDICAL OFFICER |
Venta | 52.05 | 73 078 | 1404 | 0 | 0 | enlace |
05.06.2023 | 07.06.2023 | Carter Percy H. CHIEF SCIENTIFIC OFFICER |
Venta | 52.06 | 120 102 | 2307 | 0 | 0 | enlace |
24.08.2022 | 26.08.2022 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Venta | 75.11 | 375 550 | 5000 | 0 | -0.01 | enlace |
24.08.2022 | 26.08.2022 | Durso-Bumpus Debra CHIEF PEOPLE OFFICER |
Compra | 15.01 | 75 050 | 5000 | 0 | 0.01 | enlace |
16.08.2022 | 18.08.2022 | Albers Jeffrey W. Director |
Venta | 68.41 | 1 368 200 | 20000 | 0 | -0.03 | enlace |
16.08.2022 | 18.08.2022 | Albers Jeffrey W. Director |
Compra | 8.44 | 168 800 | 20000 | 0 | 0.03 | enlace |
08.08.2022 | 10.08.2022 | Albers Jeffrey W. Director |
Venta | 70.07 | 700 700 | 10000 | 0 | -0.02 | enlace |
08.08.2022 | 10.08.2022 | Albers Jeffrey W. Director |
Compra | 6.84 | 68 400 | 10000 | 0 | 0.02 | enlace |
Instituciones | Volumen | Compartir, % |
---|---|---|
Blackrock Inc. | 6584176 | 10.76 |
Vanguard Group Inc | 6114970 | 9.99 |
Price (T.Rowe) Associates Inc | 5428955 | 8.87 |
FMR, LLC | 4348311 | 7.11 |
Wellington Management Group, LLP | 4276333 | 6.99 |
Rock Springs Capital Management, LP | 2881567 | 4.71 |
State Street Corporation | 2424200 | 3.96 |
Pictet Asset Management Holding SA | 1753547 | 2.87 |
William Blair Investment Management, LLC | 1727845 | 2.82 |
T. Rowe Price Investment Management, Inc. | 1598789 | 2.61 |
Supervisor | Título profesional | Pago | año de nacimiento |
---|---|---|---|
Mr. Michael Landsittel | Chief Financial Officer | 785.36k | 1972 (52 año) |
Dr. Percy H. Carter M.B.A., Ph.D. | Chief Scientific Officer | 761.15k | 1970 (54 año) |
Mr. Alexis A. Borisy A.M. | Co-Founder & Director | 50k | 1972 (52 año) |
Ms. Tracey L. McCain Esq. | Executive VP, Chief Legal & Compliance Officer and Secretary | 764.9k | 1968 (56 años) |
Dr. Fouad Namouni M.D. | President of Research & Development | 916.4k | 1969 (55 años) |
Jenna Cohen | Senior Director & Head of Investor Relations | N/A | |
Dr. Christopher K. Murray Ph.D. | Chief Technical Operations & Quality Officer | 338.37k | 1963 (61 año) |
Ms. Ariel Hurley | Senior VP, Finance & Principal Accounting Officer | N/A | 1974 (50 años) |
Ms. Kathryn Haviland M.B.A. | President, CEO & Director | 1976 (48 años) | |
Ms. Christina Rossi M.B.A. | Chief Operating Officer | 1976 (48 años) |
Sitio web: https://www.blueprintmedicines.com